Scholar Rock Holding (SRRK) Enterprise Value (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Enterprise Value of -$479.9 million for Q1 2026, down 31.72% year-over-year from -$702.9 million in Q1 2025, and down 30.57% quarter-over-quarter from -$367.6 million in Q4 2025.
Scholar Rock Holding (SRRK) Enterprise Value (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Enterprise Value history runs 10 years deep, the most recent figure standing at -$479.9 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 31.72% year-over-year to -$479.9 million; the TTM figure through Mar 2026 stood at -$479.9 million (down 31.72% YoY), while the FY2025 annual figure was -$367.6 million, up 15.94% from the prior year.
- Enterprise Value for Q1 2026 stood at -$479.9 million, down from -$367.6 million in the prior quarter.
- The five-year high for Enterprise Value was -$139.1 million in Q3 2024, with the low at -$479.9 million in Q1 2026.
- The 5-year median for Enterprise Value is -$295.0 million (2025), against an average of -$302.6 million.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 36.39% in 2024, then tumbled 165.8% in 2025.
- Scholar Rock Holding's Enterprise Value stood at -$315.4 million in 2022, then advanced by 11.23% to -$279.9 million in 2023, then sank by 56.21% to -$437.3 million in 2024, then grew by 15.94% to -$367.6 million in 2025, then tumbled by 30.57% to -$479.9 million in 2026.
- Business Quant data shows SRRK's Enterprise Value at -$479.9 million in Q1 2026, -$367.6 million in Q4 2025, and -$369.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | -492.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -492.09 Mn |
| Mar 31, 2026 | -479.94 Mn |
| Dec 31, 2025 | -367.56 Mn |
| Sep 30, 2025 | -369.63 Mn |
| Jun 30, 2025 | -295.01 Mn |
| Mar 31, 2025 | -364.38 Mn |
| Dec 31, 2024 | -437.28 Mn |
| Sep 30, 2024 | -139.07 Mn |
| Jun 30, 2024 | -190.49 Mn |
| Mar 31, 2024 | -238.43 Mn |
| Dec 31, 2023 | -279.94 Mn |
| Sep 30, 2023 | -218.64 Mn |
| Jun 30, 2023 | -248.73 Mn |
| Mar 31, 2023 | -275.28 Mn |
| Dec 31, 2022 | -315.36 Mn |
| Sep 30, 2022 | -343.66 Mn |
| Jun 30, 2022 | -370.69 Mn |
| Mar 31, 2022 | -210.21 Mn |
| Dec 31, 2021 | -252.99 Mn |
| Sep 30, 2021 | -246.44 Mn |